Early research (Phase 1)Looking for participantsNCT07089641
What this trial is testing
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Who this might be right for
GlioblastomaGlioblastoma, IDH-WildtypeGliosarcoma+3 more
Jonsson Comprehensive Cancer Center 50